For instance, Chae and colleagues developed nanocarrier-mediated delivery of two ICIs (i.e., anti-CTLA-4 together with anti-PD-1) with a synergic effect; thus, this treatment showed a slower tumor growth and longer mice survival compared to the monotherapy [63]. The gene discussed is CTLA4; the disease is neoplasm.